Literature DB >> 25420535

Modeling anaplastic thyroid carcinoma in the mouse.

Devora Champa1, Antonio Di Cristofano.   

Abstract

Anaplastic thyroid carcinoma is the least common form of thyroid cancer; however, it accounts for the majority of deaths associated with this family of malignancies. A number of genetically engineered immunocompetent mouse models recapitulating the genetic and histological features of anaplastic thyroid cancer have been very recently generated and represent an invaluable tool to dissect the mechanisms involved in the progression from indolent, well-differentiated tumors to aggressive, undifferentiated carcinomas and to identify novel therapeutic targets. In this review, we focus on the relevant characteristics associated with these models and on what we have learned in terms of anaplastic thyroid cancer biology, genetics, and response to targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25420535      PMCID: PMC4312228          DOI: 10.1007/s12672-014-0208-8

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  63 in total

1.  Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.

Authors:  Celine J Guigon; Laura Fozzatti; Changxue Lu; Mark C Willingham; Sheue-Yann Cheng
Journal:  Carcinogenesis       Date:  2010-03-18       Impact factor: 4.944

2.  BRAF V600E inhibition in anaplastic thyroid cancer.

Authors:  Michael H Rosove; Parvin F Peddi; John A Glaspy
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

3.  Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Authors:  Debyani Chakravarty; Elmer Santos; Mabel Ryder; Jeffrey A Knauf; Xiao-Hui Liao; Brian L West; Gideon Bollag; Richard Kolesnick; Tin Htwe Thin; Neal Rosen; Pat Zanzonico; Steven M Larson; Samuel Refetoff; Ronald Ghossein; James A Fagin
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

4.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Authors:  M Santoro; F Carlomagno; I D Hay; M A Herrmann; M Grieco; R Melillo; M A Pierotti; I Bongarzone; G Della Porta; N Berger
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

Review 5.  Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

6.  Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland.

Authors:  F Branet; P Brousset; S Krajewski; D Schlaifer; J Selves; J C Reed; P Caron
Journal:  J Clin Endocrinol Metab       Date:  1996-07       Impact factor: 5.958

Review 7.  Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets.

Authors:  Jeffrey A Knauf; James A Fagin
Journal:  Curr Opin Cell Biol       Date:  2009-02-21       Impact factor: 8.382

8.  Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.

Authors:  Devora Champa; Marika A Russo; Xiao-Hui Liao; Samuel Refetoff; Ronald A Ghossein; Antonio Di Cristofano
Journal:  Endocr Relat Cancer       Date:  2014-07-10       Impact factor: 5.678

Review 9.  Anaplastic thyroid cancer.

Authors:  Ryan L Neff; William B Farrar; Richard T Kloos; Kenneth D Burman
Journal:  Endocrinol Metab Clin North Am       Date:  2008-06       Impact factor: 4.741

10.  Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

Authors:  Xuguang Zhu; Li Zhao; Jeong Won Park; Mark C Willingham; Sheue-Yann Cheng
Journal:  Neoplasia       Date:  2014-09       Impact factor: 5.715

View more
  5 in total

1.  PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.

Authors:  Kristen Wong; Francesca Di Cristofano; Michela Ranieri; Daniela De Martino; Antonio Di Cristofano
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

Review 2.  Mouse models of thyroid cancer: A 2015 update.

Authors:  Lawrence S Kirschner; Zahida Qamri; Suresh Kari; Amruta Ashtekar
Journal:  Mol Cell Endocrinol       Date:  2015-06-27       Impact factor: 4.102

3.  Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma.

Authors:  Hai Song; Chuwen Lin; Erica Yao; Kuan Zhang; Xiaoling Li; Qingzhe Wu; Pao-Tien Chuang
Journal:  J Biol Chem       Date:  2017-01-24       Impact factor: 5.157

Review 4.  Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.

Authors:  Christina A von Roemeling; John A Copland
Journal:  Expert Opin Ther Targets       Date:  2015-09-28       Impact factor: 6.902

Review 5.  Recommendations on Surveillance for Differentiated Thyroid Carcinoma in Children with PTEN Hamartoma Tumor Syndrome.

Authors:  L A Jonker; C A Lebbink; M C J Jongmans; R A J Nievelstein; J H M Merks; E J M Nieveen van Dijkum; T P Links; N Hoogerbrugge; A S P van Trotsenburg; H M van Santen
Journal:  Eur Thyroid J       Date:  2020-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.